SAVA - All Eyes On Simufilam: Cassava Sciences' Make-Or-Break Moment

2024-06-04 05:07:02 ET

Summary

• Cassava Sciences is advancing simufilam, a Phase 3 drug for Alzheimer's, amid scrutiny over data integrity and trial conduct.
• Despite operational progress, significant concerns about simufilam's efficacy and the validity of clinical data persist.
• Financially, Cassava maintains a healthy current ratio and sufficient cash runway, assuming stable operational costs.
• Recommend a strong sell due to doubts about efficacy, data integrity, and high risks associated with their only drug, simufilam.

Introduction

Cassava Sciences ( SAVA ) is developing simufilam for the treatment of Alzheimer's disease [AD], which the company describes as a "small molecule (oral) drug that restores the normal shape and function of altered filamin A." I have been following Cassava for nearly three years and consistently recommend a "strong sell."...

For further details see: